Login / Signup

Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the ALK Gene Have Durable Responses to ALK Kinase Inhibitors.

Alexa B SchrockRussell W MadisonMark RosenzweigJustin M AllenRachel L ErlichSiao-Yi WangTarek ChidiacVodur Suresh ReddyJonathan W RiessAhmet Ersin YassaAbdur ShakirVincent A MillerBrian M AlexanderJeffrey VenstromKimberly McGregorSiraj M Ali
Published in: Lung Cancer (Auckland, N.Z.) (2020)
Rare internal inversions of ALK appear to be indicative of ALK fusions, which can be detected in RNA, and response to ALK inhibitors in patients with NSCLC. In contrast, ALK internal deletions are not associated with ALK fusions in RNA but likely represent targetable drivers themselves. These data suggest that CGP of DNA should be supplemented with immunohistochemistry or RNA-based testing to further resolve these events and match patients to effective therapies.
Keyphrases